Priority Review for Elite's abuse-deterrent opioid

Elite Pharmaceuticals Inc. (OTCQB:ELTP) said FDA accepted and granted Priority Review to an NDA for SequestOx ( ELI-200) to manage moderate to severe pain where the use of an opioid analgesic is appropriate. The PDUFA date for the abuse-deterrent formulation of oxycodone and naltrexone is July 14. ...